Vinblastine + Cyclophosphamide + Capecitabine + Nivolumab

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Childhood Solid Tumor

Conditions

Childhood Solid Tumor

Trial Timeline

Mar 26, 2019 → Jan 1, 2027

About Vinblastine + Cyclophosphamide + Capecitabine + Nivolumab

Vinblastine + Cyclophosphamide + Capecitabine + Nivolumab is a phase 1/2 stage product being developed by Bristol Myers Squibb for Childhood Solid Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT03585465. Target conditions include Childhood Solid Tumor.

What happened to similar drugs?

1 of 5 similar drugs in Childhood Solid Tumor were approved

Approved (1) Terminated (0) Active (4)

Hype Score Breakdown

Clinical
9
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03585465Phase 1/2Active